Bahaaldin Alsoufi1, Jessica H Knight2, James St Louis3, Geetha Raghuveer4, Lazaros Kochilas5. 1. University of Louisville, Louisville, KY, USA. 2. 1355University of Georgia College of Public Health, Athens, GA, USA. 3. 12273University of Missouri-Kansas City, Kansas, MO, USA. 4. Medical College of Georgia, Augusta, GA, USA. 5. 1371Emory University, Atlanta, GA, USA.
Abstract
OBJECTIVE: Conotruncal anomalies can develop aortopathy and/or aortic valve (AV) disease and AV replacement (AVR) is occasionally needed. We report long-term results and examine factors affecting survival following AVR in this group. METHODS: We queried the Pediatric Cardiac Care Consortium (PCCC, US database for interventions for congenital heart diseases) to identify patients with repaired conotruncal anomalies and AVR. Long-term outcomes were provided by the PCCC, the US National Death Index, and Organ Procurement and Transplantation Network. Competing risks analysis examined outcomes following AVR (death/transplantation, reoperation) and multivariable regression analysis assessed significant factors. RESULTS: One hundred six children with repaired conotruncal anomalies underwent AVR (1982-2003). Underlying anomaly was truncus (n = 40), d-transposition (n = 22), type-B interrupted arch (n = 16), double-outlet right ventricle (n = 12), pulmonary atresia with ventricular septal defect (n = 9), tetralogy of Fallot (n = 6), corrected transposition (n = 1). 18 (17%) had prior aortic valvuloplasty (surgical = 12, percutaneous = 6). Median age at AVR was 6.9 years (interquartile range = 2.5-12.4). AV pathophysiology was regurgitation (n = 83, 78%), stenosis (n = 9, 9%), and mixed (n = 14, 15%). AVR type was mechanical (n = 72, 68%), homograft (n = 21, 20%), and Ross (n = 13, 12%). Operative mortality was 13(12%). Infant age at AVR was risk factor (odds ratio = 55, 95% confidence interval [CI] = 6-539, P = .0006). On competing risks analysis, five years after AVR, 6% died or received transplantation, 20% had reoperation. Twenty-five years transplant-free survival was 53%. Factors associated with death after hospital discharge included mitral surgery (hazards ratio [HR] = 11, 95% CI = 3-39, P = .0002), underlying defect (HR = 2, 95% CI = 1-5, P = .446). Twenty years transplant-free survival in conotruncal anomalies group was inferior to matched children undergoing AVR for congenital non-conotruncal disease (61% vs 82%, P = .0012). CONCLUSIONS: Long-term survival following AVR in children with conotruncal anomalies is inferior to that of isolated congenital AV disease and is linked to an underlying cardiac defect. Although valve type was not associated with survival, infant age was a risk factor for operative mortality. Continuous attrition and high reoperation warrant vigilant monitoring.
OBJECTIVE: Conotruncal anomalies can develop aortopathy and/or aortic valve (AV) disease and AV replacement (AVR) is occasionally needed. We report long-term results and examine factors affecting survival following AVR in this group. METHODS: We queried the Pediatric Cardiac Care Consortium (PCCC, US database for interventions for congenital heart diseases) to identify patients with repaired conotruncal anomalies and AVR. Long-term outcomes were provided by the PCCC, the US National Death Index, and Organ Procurement and Transplantation Network. Competing risks analysis examined outcomes following AVR (death/transplantation, reoperation) and multivariable regression analysis assessed significant factors. RESULTS: One hundred six children with repaired conotruncal anomalies underwent AVR (1982-2003). Underlying anomaly was truncus (n = 40), d-transposition (n = 22), type-B interrupted arch (n = 16), double-outlet right ventricle (n = 12), pulmonary atresia with ventricular septal defect (n = 9), tetralogy of Fallot (n = 6), corrected transposition (n = 1). 18 (17%) had prior aortic valvuloplasty (surgical = 12, percutaneous = 6). Median age at AVR was 6.9 years (interquartile range = 2.5-12.4). AV pathophysiology was regurgitation (n = 83, 78%), stenosis (n = 9, 9%), and mixed (n = 14, 15%). AVR type was mechanical (n = 72, 68%), homograft (n = 21, 20%), and Ross (n = 13, 12%). Operative mortality was 13(12%). Infant age at AVR was risk factor (odds ratio = 55, 95% confidence interval [CI] = 6-539, P = .0006). On competing risks analysis, five years after AVR, 6% died or received transplantation, 20% had reoperation. Twenty-five years transplant-free survival was 53%. Factors associated with death after hospital discharge included mitral surgery (hazards ratio [HR] = 11, 95% CI = 3-39, P = .0002), underlying defect (HR = 2, 95% CI = 1-5, P = .446). Twenty years transplant-free survival in conotruncal anomalies group was inferior to matched children undergoing AVR for congenital non-conotruncal disease (61% vs 82%, P = .0012). CONCLUSIONS: Long-term survival following AVR in children with conotruncal anomalies is inferior to that of isolated congenital AV disease and is linked to an underlying cardiac defect. Although valve type was not associated with survival, infant age was a risk factor for operative mortality. Continuous attrition and high reoperation warrant vigilant monitoring.
Authors: Bahaaldin Alsoufi; William G Williams; Zhongdong Hua; Sally Cai; Tara Karamlou; Chee Ching Chan; John G Coles; Glen S Van Arsdell; Christopher A Caldarone Journal: Eur J Cardiothorac Surg Date: 2007-01-09 Impact factor: 4.191
Authors: Christian P Brizard; Alice Lee; Diana Zannino; Andrew M Davis; Tyson A Fricke; Yves d'Udekem; Igor E Konstantinov; Johann Brink; Michael M H Cheung Journal: J Thorac Cardiovasc Surg Date: 2017-04-02 Impact factor: 5.209
Authors: Bradley S Marino; Gil Wernovsky; Doff B McElhinney; Abbas Jawad; Dieuwertje L Kreb; Suzan F Mantel; Wendy L van der Woerd; Danielle Robbers-Visser; Rita Novello; J William Gaynor; Thomas L Spray; Meryl S Cohen Journal: Cardiol Young Date: 2006-10 Impact factor: 1.093
Authors: Anusha Jegatheeswaran; Brian W McCrindle; Eugene H Blackstone; Marshall L Jacobs; Gary K Lofland; Earl H Austin; Thomas Yeh; Victor Morell; Jeffrey P Jacobs; Richard A Jonas; Sally Cai; Jeevanantham Rajeswaran; Marco Ricci; William G Williams; Christopher A Caldarone; William M DeCampli Journal: J Thorac Cardiovasc Surg Date: 2010-11 Impact factor: 5.209
Authors: Joseph A Dearani; Harold M Burkhart; John M Stulak; Thoralf M Sundt; Hartzell V Schaff Journal: Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu Date: 2009
Authors: Bahaaldin Alsoufi; Brian Schlosser; Courtney McCracken; Ritu Sachdeva; Brian Kogon; William Border; William T Mahle; Kirk Kanter Journal: J Thorac Cardiovasc Surg Date: 2015-09-28 Impact factor: 5.209
Authors: John W Brown; Parth M Patel; Jiuann-Huey Ivy Lin; Asma S Habib; Mark D Rodefeld; Mark W Turrentine Journal: Ann Thorac Surg Date: 2016-04-01 Impact factor: 4.330